Cross-Border Deals Now Define Cannabis M&A

LOS ANGELES – The global Cannabis industry has entered a new phase, one where the most influential deals are no longer being struck in North America, but across continents. The month of June kicked off with a transaction that will be studied for years to come.

Two Australian operators, one with roots in clinical Cannabis and the other built on the domestic market scale, formally merged into a single, cross-continental entity. The strategic logic behind this consolidation is already being replicated in Germany, the United Kingdom, and Southern Africa.

The template is clear.
The race to execute it is underway.

The Deal That Sets the Tone

On June 1, 2026, Little Green Pharma (LGP) completed its scheme of arrangement with Cannatrek, merging into a vertically integrated LGP Cannatrek Group spanning cultivation, EU-GMP and AU-GMP certified manufacturing, distribution, digital health, and European operations. Under this structure, Cannatrek shareholders now hold a 60.5% stake in the combined entity, while existing LGP shareholders retain 39.5%.

On a pro-forma basis using FY25 results, the combined group generates approximately A$112 million in revenue and A$13 million in adjusted EBITDA, implying a transaction multiple of roughly 8.5x EBITDA against A$110 million enterprise value.

At first glance, that multiple looks full.
In context, it is precise.

Both parties acquired something the other could not have built fast enough independently.

Cannatrek brought what LGP needed most – domestic Australian market scale and cash generation. As LGP Managing Director Paul Long put it when the merger was first announced, Cannatrek “is the second-largest brand in the domestic medicinal market, profitable, vertically integrated, and operating with a strong balance sheet,” while LGP had spent years building out European infrastructure. The payoff? Cannatrek’s balance sheet now backs LGP’s Denmark facility, the largest medical Cannabis production facility in Europe, currently operating with excess capacity available to absorb Cannatrek product lines bound for European markets.

LGP, in turn, gave Cannatrek something no amount of domestic revenue growth could provide – a platform sitting on the right side of one of the fastest-expanding regulated markets in the world.

Why Europe Is the Strategic Anchor

The M&A logic in 2026 runs through Europe and, specifically, Germany. The country’s €670 million medical Cannabis market is currently serving roughly one million patients – figures that would have seemed implausible as recently as 2022. The April 2024 Cannabis Act (Cannabisgesetz, CanG) removed the plant from Germany’s Narcotics Act (Betäubungsmittelgesetz, BtMG), eliminated prescription quotas, and triggered a wave of telemedicine prescribing that drove prescription volumes up over 3,300% [!] in under two years. More than 50 tons of Cannabis flower were imported into Germany in Q1 2026 alone, confirming its status as the largest medical Cannabis market outside North America.

The broader European picture compounds that opportunity. The European medical Cannabis market was valued at roughly $3.06 billion in 2025 and is projected to exceed $13.1 billion by 2034, representing consistent double-digit annual growth through the next decade. For any operator without EU-GMP certified manufacturing and established distribution, that market is effectively closed.

Today, EU-GMP compliance is not a box to check.
It is the barrier that determines who participates.
That compliance constraint is precisely what 2026’s cross-border deal wave is designed to solve.

Four Deals in One Logic

The LGP-Cannatrek closure sits at the top of a 2026 cross-border transaction stack that, taken together, defines what strategic Cannabis M&A now looks like.

Curaleaf – Four 20 Pharma GmbH (closed April 30, 2026)

Curaleaf completed the buyout of the remaining 45% stake in Germany’s Four 20 Pharma, giving it full ownership of the EU-GMP and GDP licensed medical Cannabis producer and distributor, and tightening a vertically integrated seed-to-patient supply chain running from cultivation sources in Portugal and Canada through to licensed distribution across Germany. This is the North American MSO playbook, tested across dozens of regulated U.S. markets and transplanted into Europe one licensed asset. The original 2022 deal anchored the relationship at approximately $32.3 million EV; the 2026 buyout of the remaining 45% completes a four-year vertical integration sequence that now gives Curaleaf pharmacy network access, EU-GMP production, and established brand distribution under a single P&L.

Tilray – Lyphe (announced April 2026)

One of the UK’s earliest clinic and distribution platforms folds into Tilray’s vertical model. The deal is undisclosed in value but unambiguous in direction as the UK clinic segment is consolidating into producer-owned stacks, and whoever controls the clinic relationship – controls the prescribing channel. In a market where product access still depends heavily on specialist clinic referral, this is not peripheral infrastructure, but rather the front door.

Canify AG – MG Health Limited (announced March 12, 2026)

Perhaps the most structurally instructive deal in the 2026 cohort. MG Health will provide EU-GMP certified flower cultivation and extraction from its facility 2,000 meters high in the Maluti Mountains of Lesotho. Canify will contribute pharmaceutical processing, regulatory management, and distribution through its established pharmacy network, as well as its Canify Clinics telemedicine platform. The combined group will have commercial presence in more than seven [!] countries. This is selective vertical integration without redundancy [each party contributes what the other cannot replicate] and the result is a locked supply chain from cultivation altitude to pharmacy shelf.

The Domestic Parallel: Buying Segments, Not Scale

The same acquisition rationale playing out cross-border is visible in domestic deals, which reinforces that this is a structural shift in how operators think about M&A as non-international trend.

• Aurora Cannabis acquired Safari Flower Company on April 15, 2026, for C$26.5 million – an EU-GMP certified cultivator and manufacturer that adds specific certified production capacity rather than generic scale.
• Canopy Growth completed its acquisition of MTL Cannabis on March 16, 2026, in a transaction valued at approximately C$125 million on a fully-diluted equity basis, explicitly targeting MTL’s premium flower supply and international export capability, not its market footprint per se.
• And the most closely watched domestic deal in Europe – Organigram’s acquisition of the Berlin-based Sanity Group in February 2026 — marked the largest bet on Germany’s Cannabis market by a North American operator to date. Sanity’s revenues grew from €9 million in 2023 to €60 million in 2025, with gross margins expanding from 15% to 47%. The premium paid reflects not those historical numbers alone, but the value of its brands, its pharmacy network, its logistics facility near Frankfurt, and its adult-use pilot operations in Switzerland.

The pattern is identical in each case.
Buyers are pricing capability gaps (brand, channel, compliance infrastructure, clinical distribution), not raw production capacity.

The Data Behind the Wave

According to Cannamonitor’s M&A tracker, year-to-date 2026 activity spans 74 transactions across the U.S. (30), Canada (18), Australia (8), and Germany (5), comprising 23 acquisitions, 14 asset sales, one merger, four IPOs, 16 equity raises, and 16 debt facilities. Total consideration: US$2.1 billion in M&A plus US$1.5 billion in equity and debt.

Australia’s 8 transactions and Germany’s 5 are no longer footnotes to North American deal volume. They represent where the cross-border thesis is being validated and repriced in real time.

The top 15 Cannabis producers now control nearly 48% of global licensed cultivation capacity, with mid-size operators at 32% and independent growers at 20%. That concentration curve is steepening, and the 2026 deal data suggests it will continue to do so, not through mass consolidation, but through targeted acquisitions of specific compliance, brand, and distribution assets.

Vertical Integration: Selective, Not Total

One analytical conclusion from 2026’s deal activity deserves direct attention. Vertical integration as a blanket strategy, owning every stage from seed to sale, has largely been retired by operators who tried it and found the capital requirements untenable. What has replaced it is something more precise: selective vertical integration, in which the strategic call is not whether to integrate, but which stages to own outright, which to access through long-term supply agreements, and which to leave to specialist partners.

The Canify–MG Health structure is the clearest expression of this logic. Canify does not need to own a cultivation facility in Lesotho outright. It needs guaranteed, EU-GMP compliant supply from a low-cost jurisdiction with reliable logistics. MG Health doesn’t need to build a German pharmacy network from zero. It needs a regulatory-ready distribution platform that moves its product. The merger formalizes a supply relationship that already existed and adds the ownership structure required to align incentives across the full value chain.

LGP-Cannatrek runs the same logic at larger scale. LGP’s Denmark cultivation facility had excess capacity. Cannatrek had product lines and a patient base needing EU-market access. The merger does not create a new supply chain. It connects two that were already operating, under shared governance.

That’s what mature M&A looks like in a regulated industry:

• filling specific capability gaps with targeted assets, then
• integrating operations around shared infrastructure rather than building it twice.

What Comes Next

The global legal Cannabis market reached $38 billion in 2025, and it’s projected to grow at a CAGR of 14%-18% through 2035. The U.S. still accounts for the majority of that revenue, but the growth rate differential increasingly favors Europe and Asia-Pacific, which is precisely where the cross-border deal activity is concentrating.

Germany’s government has committed to reviewing adult-use pilot program data in late 2026, with potential nationwide retail expansion potentially following in 2027. If the second pillar of Germany’s Cannabis reform proceeds, market size estimates reset dramatically upward, adding an entirely new consumer segment on top of an already €670 million-plus medical base. That regulatory optionality is already being priced into acquisition premiums for German platform assets, as the Organigram-Sanity deal structure [with up to €113.8 million in earnout tied to financial performance] makes explicit.

For operators that have not yet established a position in a regulated international market, the window is narrowing. EU-GMP certified assets capable of supporting multi-market distribution are not abundant, and the operators already acquiring them are doing so precisely because they cannot be replicated quickly. The compliance runway alone, from facility construction to EU-GMP certification to market authorization, runs 3-5 years in most jurisdictions.

The LGP-Cannatrek merger is the first transaction to formally integrate Asia-Pacific and European Cannabis supply and demand under one operator. More will follow. The determinant of which operators close those deals on favorable terms, and which pay late-cycle premiums for diminishing asset availability, is the speed with which management teams accept a simple reality:

In 2026, Cannabis M&A is priced on what the buyer cannot build alone.